Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Phentermine

Known as: alpha,alpha-Dimethylphenethylamine, Phentermine [Chemical/Ingredient], Phenterminum 
A natural monoamine alkaloid derivative and a sympathomimetic stimulant with appetite suppressant property. Phentermine, which was part of the Fen… Expand
National Institutes of Health

Related topics

Related topics

38 relations

Narrower (11)

2-methyl-2-nitro-1-phenylpropane4-iodophentermineAdipex-PDuromine
Expand
24 HR Phentermine 11.25 MG / topiramate 69 MG Extended Release Oral Capsule [Qsymia]Appetite Suppression [PE]ArteriosclerosisChild
Expand

Broader (5)

Adrenergic AgentsAmphetamineAppetite DepressantsCentral Nervous System Stimulants
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Long-term drug treatment for obesity: a systematic and clinical review.
IMPORTANCE Thirty-six percent of US adults are obese, and many cannot lose sufficient weight to improve health with lifestyle… Expand
  • table 1
  • figure I
  • table 2
  • table 2
  • table 3
Highly Cited
2012
Highly Cited
2012
Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
A 56‐week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled‐release combination of… Expand
Highly Cited
2012
Highly Cited
2012
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension…
Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2011
Highly Cited
2011
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled…
BACKGROUND Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases… Expand
Review
2008
Review
2008
Health services research
DL-FENFLURAMINE AND PHENTERMINE USE IN OBESE ADOLESCENTS: THE RELATIONSHIP BETWEEN AGE AND TREATMENT SUCCESS. SL Emerson_ CM… Expand
Highly Cited
2005
Highly Cited
2005
Obesity
Objective: This study aimed to investigate the effect of exercise intensity on visceral adipose tissue (VAT) and liver fat… Expand
  • figure 1
  • table 2
  • table 3
  • table 5
Highly Cited
2001
Highly Cited
2001
Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
A large body of evidence supports the hypothesis that mesolimbic dopamine (DA) mediates, in animal models, the reinforcing… Expand
Highly Cited
2000
Highly Cited
2000
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.
Familial primary pulmonary hypertension is a rare autosomal dominant disorder that has reduced penetrance and that has been… Expand
Highly Cited
1997
Highly Cited
1997
Valvular heart disease associated with fenfluramine-phentermine.
BACKGROUND Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration… Expand
Highly Cited
1997
Highly Cited
1997
Valvular heart disease associated with fenfluramine-phentermine.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE